Market Research Report
Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016
|Published by||Global Markets Direct||Product code||410976|
|Published||Content info||52 Pages
|Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016|
|Published: December 30, 2016||Content info: 52 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016, provides an overview of the Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline landscape.
Charcot-Marie-Tooth disease type 1A (CMT1A) is a type of inherited neurological disorder that affects the peripheral nerves. Symptoms include distal weakness and atrophy, sensory loss, foot deformities, and slow nerve conduction velocity. The disorder is caused by a duplication of the PMP22 gene on Chromosome 17. Symptomatic treatment includes pain medication, physical therapy and surgery.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Charcot-Marie-Tooth Disease Type I A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.